Action 1BT ENLIVEX THERAPEUTICS LTD.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Enlivex Therapeutics Ltd. Deutsche Boerse AG

Actions

1BT

IL0011319527

Marché Fermé - Deutsche Boerse AG
Autres places de cotation
 08:00:12 28/06/2024 		Varia. 5j. Varia. 1 janv.
1,37 EUR +9,60% Graphique intraday de Enlivex Therapeutics Ltd. +14,17% -40,43%
24/06 Enlivex Therapeutics annonce que le premier patient a été traité dans le cadre de l'essai de phase 1/2 sur l'arthrose du pouce MT
24/06 Enlivex Therapeutics Ltd. annonce le dosage du premier patient dans le cadre d'un essai de phase I/II randomisé et contrôlé par placebo évaluant AllocetraTM chez 46 patients souffrant d'arthrose du pouce CI

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Enlivex Therapeutics Says First Patient Dosed in Phase 1/2 Thumb Osteoarthritis Trial
Enlivex Therapeutics : Announces the Dosing of the First Patient in a Randomized, Placebo-Controlled Phase I/II Trial Evaluating Allocetra in up to 46 Patients with Thumb Osteoarthritis
Enlivex Announces the Dosing of the First Patient in a Randomized, Placebo-Controlled Phase I/II Trial Evaluating AllocetraTM in up to 46 Patients with Thumb Osteoarthritis
Enlivex Announces the Dosing of the First Patient in a Randomized, Placebo-Controlled Phase I/II Trial Evaluating AllocetraTM in up to 46 Patients with Thumb Osteoarthritis
Enlivex Therapeutics Ltd. Announces the Dosing of the First Patient in a Randomized, Placebo-Controlled Phase I/II Trial Evaluating AllocetraTM in up to 46 Patients with Thumb Osteoarthritis
Join Enlivex Therapeutics’ Chief Executive Officer for a Live Investor Webinar and Q&A Session on June 25
Join Enlivex Therapeutics’ Chief Executive Officer for a Live Investor Webinar and Q&A Session on June 25
Enlivex Announces Positive Interim Data Readout from a Phase I/II Trial Evaluating Allocetra in End-Stage Knee Osteoarthritis
Enlivex Announces Positive Interim Data Readout from a Phase I/II Trial Evaluating Allocetra in End-Stage Knee Osteoarthritis
ENLIVEX THERAPEUTICS : CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF MARCH 31, 2024 AND DECEMBER 31, 2023 AND FOR THE THREE MONTH PERIODS ENDED MARCH 31, 2024 AND 2023 ENLIVEX THERAPEUTICS LTD. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF MARCH 31, 2024 AND DECEMBER 31, 2023 AND FOR THE THREE MONTH PERIODS ENDED MARCH 31, 2024 AND 2023 INDEX TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Form 6 K
Enlivex Therapeutics Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
Enlivex Receives Regulatory Authorization for the Initiation of a Placebo-Controlled Phase I/II Trial Evaluating Allocetra in Up To 46 Patients with Thumb Osteoarthritis
Enlivex Receives Regulatory Authorization for the Initiation of a Placebo-Controlled Phase I/II Trial Evaluating Allocetra in Up To 46 Patients with Thumb Osteoarthritis
Enlivex Receives Regulatory Authorization for the Initiation of a Placebo-Controlled Phase I/II Trial Evaluating Allocetra in Up To 46 Patients with Thumb Osteoarthritis
Enlivex Therapeutics : Immediate Report
Enlivex Therapeutics Closes up to $15 Million Registered Direct Offering
Enlivex Therapeutics to Launch Registered Direct Offering; Shares Fall
Enlivex Therapeutics Announces up to $15 Million Registered Direct Offering
Enlivex Therapeutics : Report of Periodic or Interim Report
Enlivex CEO Issues Letter to Shareholders – Perspectives on Recent Events
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action ENLV
  4. Action 1BT
  5. Actualités Enlivex Therapeutics Ltd.
  6. Autres langues